Novacyt S.A. ("Novacyt", the "Company" or the "Group")

DHSC Claim Update – Trial Date Listed

Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt that the hearing of the case between Primer Design Ltd / Novacyt and the DHSC has been listed to commence on 10 June 2024 and is expected to last 16 days.

The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230129005018/en/

The NOVACYT Stock at the time of publication of the news with a fall of -8,01 % to 0,880EUR on Tradegate stock exchange (26. Januar 2023, 13:08 Uhr).